A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy

Lung Cancer

Volumn 99, Issue , 2016, Pages 186-193

  Yoh, Kiyotaka ^a   Hosomi, Yukio ^b   Kasahara, Kazuo ^c   Yamada, Kazuhiko ^d   Takahashi, Toshiaki ^e   Yamamoto, Nobuyuki ^f   Nishio, Makoto ^g   Ohe, Yuichiro ^h   Koue, Toshiko ⁱ   Nakamura, Takashi ⁱ   Enatsu, Sotaro ⁱ   Lee, Pablo ⁱ   Ferry, David ⁱ   Tamura, Tomohide ^j   Nakagawa, Kazuhiko ^k  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^d KURUME UNIVERSITY HOSPITAL   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^g CANCER INSTITUTE HOSPITAL   (Japan)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁱ ELI LILLY AND COMPANY   (United States)

^j ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^k KINKI UNIVERSITY   (Japan)

more..

Author keywords

Docetaxel; Japan; Non small cell lung cancer; Ramucirumab; Randomized phase II trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DOCETAXEL; PLACEBO; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM; TAXOID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DEATH; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSGEUSIA; EPISTAXIS; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FISTULA; HAND FOOT SYNDROME; HICCUP; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; INFUSION RELATED REACTION; INSOMNIA; JAPANESE (PEOPLE); KIDNEY FAILURE; LEUKOPENIA; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING; AGED; CANCER STAGING; CLINICAL TRIAL; DISEASE EXACERBATION; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; RETREATMENT; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM; RETREATMENT; RISK FACTORS; TAXOIDS; TREATMENT OUTCOME;

EID: 84978802703     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.07.019     Document Type: Article

References (22)

1. [1] Fontanella, C., Ongaro, E., Bolzonello, S., Guardascione, M., Fasola, G., Aprile, G., Clinical advances in the development of novel VEGFR2 inhibitors. Ann. Transl. Med., 2, 2014, 123.
2. [2] Spratlin, J.L., Cohen, R.B., Eadens, M., Gore, L., Camidge, D.R., Diab, S., Leong, S., O'Bryant, C., Chow, L.Q.M., Serkova, N.J., Meropol, N.J., Lewis, N.L., Chiorean, E.G., Fox, F., Youssoufian, H., Rowinsky, E.K., Eckhardt, S.G., Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 28 (2010), 780–787.
3. [3] Fuchs, C.S., Tomasek, J., Yong, C.J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L.V., Aprile, G., Ferry, D.R., Melichar, B., Tehfe, M., Topuzov, E., Zalcberg, J.R., Chau, I., Campbell, W., Sivanandan, C., Pikiel, J., Koshiji, M., Hsu, Y., Liepa, A.M., Gao, L., Schwartz, J.D., Tabernero, J., Regard trial investigators, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (2014), 31–39.
4. [4] Wilke, H., Muro, K., Van Cutsem, E., Oh, S.C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.Y., Cunningham, D., Rougier, P., Komatsu, Y., Ajani, J., Emig, M., Carlesi, R., Ferry, D., Chandrawansa, K., Schwartz, J.D., Ohtsu, A., Rainbow Study Group, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind randomised phase 3 trial. Lancet Oncol. 15 (2014), 1224–1235.
5. [5] Tabernero, J., Yoshino, T., Cohn, A.L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.E., Portnoy, D.C., Van Cutsem, E., Grothey, A., Prausova, J., Garcia-Alfonso, P., Yamazaki, K., Clingan, P.R., Lonardi, S., Kim, T.W., Simms, L., Chang, S.C., Nasroulah, F., Raise Study Investigators, Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised double-blind, multicentre, phase 3 study. Lancet Oncol. 16 (2015), 499–508.
6. [6] Garon, E.B., Cao, D., Alexandris, E., John, W.J., Yurasov, S., Perol, M., A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clin. Lung Cancer 13 (2012), 505–509.
7. [7] Garon, E.B., Ciuleanu, T.E., Arrieta, O., Prabhash, K., Syrigos, K.N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R.D., Pikiel, J., Czyzewicz, G., Orlov, S.V., Lewanski, C.R., Thomas, M., Bidoli, P., Dakhil, S., Gans, S., Kim, J.H., Grigorescu, A., Karaseva, N., Reck, M., Cappuzzo, F., Alexandris, E., Sashegyi, A., Yurasov, S., Perol, M., Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384 (2014), 665–673.
8. [8] National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. 2015 http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf (accessed 09.09.15).
9. [9] Mitsudomi, T., Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. Transl. Lung Cancer Res. 3 (2014), 205–211.
10. [10] Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., Meyerson, M., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
11. [11] Hayakawa, K., [Revised by the Japan lung cancer society: guideline for diagnosis and treatment of lung cancer]. Gan To Kagaku Ryoho 38 (2011), 1273–1276.
12. [12] Kuribayashi, K., Tabata, C., Cutting-edge medical treatment for advanced non-small cell lung cancer. J. Cancer Biol. Res., 2, 2014, 1026.
13. [13] Fossella, F.V., R, DeVore, Kerr, R.N., Crawford, J., Natale, R.R., Dunphy, F., Kalman, L., Miller, V., Lee, J.S., Moore, M., Gandara, D., Karp, D., Vokes, E., Kris, M., Kim, Y., Gamza, F., Hammershaimb, L., The TAX320 non–small-cell lung cancer study group, randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non–small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J. Clin. Oncol. 18 (2000), 2354–2362.
14. [14] Shepherd, F.A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., M. O'Rourke, N., Levitan, L., Gressot, M., Vincent, R., Burkes, S., Coughlin, Y., Kim, J., Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18 (2000), 2095–2103.
15. [15] Garassino, M.C., Martelli, O., Broggini, M., Farina, G., Veronese, S., Rulli, E., Bianchi, F., Bettini, A., Longo, F., Moscetti, L., Tomirotti, M., Marabese, M., Ganzinelli, M., Lauricella, C., Labianca, R., Floriani, I., Giaccone, G., Torri, V., Scanni, A., Marsoni, S., Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 14 (2013), 981–988.
16. [16] Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., Shepherd, F.A., The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14 (2009), 253–263.
17. [17] Kunitoh, H., Watanabe, K., Onoshi, T., Furuse, K., Niitani, H., Taguchi, T., Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J. Clin. Oncol. 14 (1996), 1649–1655.
18. [18] The Japan Lung Cancer Society [Guideline for Diagnosis and Treatment of Lung Cancer 2015]. 2015 http://www.haigan.gr.jp/modules/guideline/index.php?content_id=3 (accessed 02.12.15).
19. [19] Maruyama, R., Nishiwaki, Y., Tamura, T., Yamamoto, N., Tsuboi, M., Nakagawa, K., Shinkai, T., Negoro, S., Imamura, F., Eguchi, K., Takeda, K., Inoue, A., Tomii, K., Harada, M., Masuda, N., Jiang, H., Itoh, Y., Ichinose, Y., Saijo, N., Fukuoka, M., Phase III study V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol. 26 (2008), 4244–4252.
20. [20] Stein, M.N., Chow, L.Q.M., Smith, D.C., Shepard, D.R., Wang, D., Powderly, J.D., Gao, L., Lin, Y., Koshiji, M., Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors. J. Clin. Oncol., 32 abstr, 2014, e13539.
21. [21] Doebele, R.C., Spigel, D., Tehfe, M., Thomas, S., Reck, M., Verma, S., Eakle, J., Bustin, F., Goldschmidt, J. Jr., Cao, D., Alexandris, E., Yurasov, S., Camidge, D.R., Bonomi, P., Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer 121 (2015), 883–892.
22. [22] Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T.C., Pless, M., Muller, T., Lim, H.L., Desch, C., Szondy, K., Gervais, R., Shaharyar, C., Manegold, S., Paul, P., Paoletti, L., Einhorn, P.A., Bunn Jr., Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22 (2004), 1589–1597.